Further development of CAR-T cell therapy: Safe transport for life-saving treatments

CAR-T cell therapy is at the forefront of personalized medicine, offering promising results for patients battling hematological malignancies. These innovative therapies harness the power of the patient's own immune cells to target and eliminate cancer cells, offering a glimmer of hope in the fight against cancer.

At Consarctic, we recognize the importance of safely transporting these valuable cells from patients to pharmaceutical manufacturers like Roche, Bristol-Myers Squibb, and others, where they undergo careful processing and bioengineering. Ensuring the integrity and viability of CAR T cells during transport is critical to the success of these groundbreaking therapies.

With our expertise in cryogenic transport, we utilize state-of-the-art technologies and strict protocols to ensure optimal conditions throughout the entire transport process. Our robust cryogenic transport containers, including the ASR 25+, are available in various designs and sizes for the safe transport of biological samples. These containers are equipped with data loggers to ensure precise temperature monitoring and regulatory compliance.

Working closely with partners from the pharmaceutical industry and leading medical centers, we ensure seamless logistics and ensure that CAR-T cells reach their destination with the utmost care and efficiency. By prioritizing patient safety and therapeutic efficacy, Consarctics' cryotransport solutions play a critical role in advancing the advancement of CAR-T cell therapies, giving patients hope and paving the way for a better future in cancer treatment. Join us on our mission to advance healthcare through innovation and our pursuit of excellence.